This study aimed to investigate the prevalence of impaired renal function at the time of Heart Failure diagnosis and its correlation with short and long-term outcomes in a real-world cohort of Heart Failure patients.
RWE is becoming a valuable addition to randomized controlled clinical trials to better understand the mechanisms and outcomes of cancer treatments. However, most RWD is locked in a non-uniform patient reporting system by hospitals and healthcare professionals. Download our use case in immuno-oncology by completing the form and read how artificial intelligence can help unlock real-world evidence in immunotherapy.
LynxCare is facilitating RWE collaborations between a growing network of hospitals and life science companies in Europe. These federated networks enable qualitative RWE generation at scale across numerous therapeutic areas within a strict legal & ethical framework.